EMA: A Differentiation Antigen Related to Node Metastatic Capacity of Breast Carcinomas

Luna-Moré, Sebastián; Ríus, Francisca; Weil, Bernardo; Jimenez, Ana; Bautista, María Dolores; Pérez-Mellado, Alfonso

doi:10.1078/0344-0338-00055

Cited by 20 publications

(20 citation statements)

References 30 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significantly EMA expressing tumors also show an increased relapse free survival. These observations are supported by the findings of Luna-More et al who reported that EMA negative tumors are high grade, ER and PR negative and are more frequently associated with positive axillary lymph nodes [10].…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Comparison of Immunohistochemistry with Conventional Histopathology for Evaluation of Sentinel Lymph Node in Breast Cancer

et al. 2010

View full text Add to dashboard Cite

The best method of pathological evaluation of sentinel lymph node in breast cancer has not been agreed upon. Immunohistochemical (IHC) techniques have shown a greater sensitivity over conventional histology for the detection of micrometastais. The aim of the study was to determine whether IHC for Epithelial Membrane Antigen (EMA) on the sentinel node could be more sensitive than conventional histology for diagnosing micrometastasis in sentinel lymph nodes. Eighty-four clinically node negative breast cancer patients underwent sentinel node biopsy at time of surgery for breast cancer. The node was subjected to conventional histopathology as well as IHC for EMA. The sensitivity of histology viz a viz IHC for EMA for detection of sentinel node metastasis was 88% and the specitficity was 96%. The overall diagnostic accuray of histology viz a viz IHC was 93%. There were 4 patients with micrometastasis (<2.0 mm), which were positive on IHC but negative on histology. Two patients with poorly differentiated breast cancer had a false negative IHC for EMA result as compared to histology. Immunohistochemistry for Epithelial Membrane Antigen can increase the detection rate of micrometastasis in sentinel lymph node. This can have important bearing on deciding the need of adjuvant systemic therapy. A false negative result for EMA may be seen in patients with poorly differential cancer. Therefore the best policy seems to employ both histopathology and IHC for EMA for the comprehensive evaluation of sentinel lymph node in breast cancer.

show abstract

Section: Discussionsupporting

confidence: 81%

“…Epithelial membrane antigen (EMA), also known as MUC 1, is a mucinous glycoprotein fixed to the luminal domain of epithelial cell membrane of normal breast ducts [2]. In breast cancer, EMA expression is upregulated and it is an indicator of poor prognosis [3].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Immunohistochemistry with Conventional Histopathology for Evaluation of Sentinel Lymph Node in Breast Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…On the other hand, absence of MUC1 expression also occurred and was associated with the absence of estrogen receptors (ERs) and progesterone receptors (PRs) in several breastcancerstudies.Thesefindingssupporttheobservation by Luna-More et al [17] that tumors of the human breast negativeforMUC1arehigh-grade,areERandPRnegative andassociatedwithpositiveaxillarylymphnodes.Otherstudies also related low or negative MUC1 expression to higher tumorgradeandpoorprognosis [18,19].…”

Section: Introductionsupporting

confidence: 54%

Evaluation of a Novel Anti-Mucin 1 (MUC1) Antibody (PankoMab) as a Potential Diagnostic Tool in Human Ductal Breast Cancer; Comparison with Two Established Antibodies

Dian¹,

Kühn²,

Mayr

et al. 2009

Oncol Res Treat

View full text Add to dashboard Cite

Aim: PankoMab is a novel antibody that recognizes a tumor-specific epitope of Mucin 1 (MUC1). The aim of this study was the evaluation of PankoMab as a potential diagnostic tool and its comparison with two established antibodies against MUC1 in human ductal breast cancer. Materials and Methods: Breast carcinomas were obtained from 82 patients. MUC1 expression and hormone receptor status were determined by immunohistochemistry of paraffin-embedded material. Results: PankoMab revealed strong correlation to hormone receptor expression. DF3 showed no correlation with grading, lymph node involvement and/or estrogen receptor (ER) expression. In the subgroup of lymph node-positive and ER-negative tumors, we saw a significantly reduced DF3 staining in G3 tumors compared to G2 tumors. VU-4-H5 showed increased staining intensity in correlation with increased grading. In addition, we also identified a significantly higher expression of the VU-4-H5 epitope in lymph node-positive carcinomas compared to carcinomas without lymph node involvement. Conclusion: PankoMab revealed strong correlation to hormone receptor expression in ductal carcinoma of the breast. VU-4-H5 showed increased staining intensity in correlation with increased grading and lymph node involvement. PankoMab and VU-4-H5 staining could be a useful combination in ductal breast cancer prognosis by immunohistochemistry.

show abstract

“…Most samples did not show any polarization of the reaction which, on the other hand, constituted the hallmark of normal and benign tissue sample staining. In 330 breast carcinomas, Luna-Moré et al (2001) have found that a linear (membrane) pattern was the least node-metastasizing, while the negative pattern was the most with the exception of micropapillary carcinomas. Rahn et al (2001) have pointed out that an extended expression of MUC1 in cancer cells correlates with a better prognosis, although expression at the apical level is an accurate indicator of functional differentiation.…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemical (IHC) MUC1 detection studies have included diverse anti-MUC1 monoclonal antibodies (MAbs) against the extracellular domain, mainly against different sequences from the VNTR (Griffiths et al 1987;Croce et al 1997;Luna-Moré et al 2001;Rahn et al 2001) and also against the carbohydrate side chains (Renkonen et al 1997;Nakagoe et al 2002). The present study was developed to find evidence about MUC1 pattern expression in breast carcinoma by use of an anti-MUC1 CT MAb, because it is a reliable indicator of the abundance of cell-associated MUC1 mucin.…”

mentioning

confidence: 99%

Patterns of MUC1 Tissue Expression Defined by an Anti-MUC1 Cytoplasmic Tail Monoclonal Antibody in Breast Cancer

Croce

Isla-Larrain

Rua

et al. 2003

J Histochem Cytochem.

View full text Add to dashboard Cite

EMA: A Differentiation Antigen Related to Node Metastatic Capacity of Breast Carcinomas

Cited by 20 publications

References 30 publications

Comparison of Immunohistochemistry with Conventional Histopathology for Evaluation of Sentinel Lymph Node in Breast Cancer

Comparison of Immunohistochemistry with Conventional Histopathology for Evaluation of Sentinel Lymph Node in Breast Cancer

Evaluation of a Novel Anti-Mucin 1 (MUC1) Antibody (PankoMab) as a Potential Diagnostic Tool in Human Ductal Breast Cancer; Comparison with Two Established Antibodies

Patterns of MUC1 Tissue Expression Defined by an Anti-MUC1 Cytoplasmic Tail Monoclonal Antibody in Breast Cancer

Contact Info

Product

Resources

About